Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3000202 in Moderate to Severe Systemic Lupus Erythematosus
NCT07409181Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of BI 3000202 in systemic lupus erythematosus (SLE), sponsored by Boehringer Ingelheim. Started Apr 2026; status: recruiting.
02
Drugs
BI 3000202
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07409181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409181.